You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Now Available

Change the outlookfor dry eye disease

Only CEQUA^™ features NCELL^™, an innovative technology that helps improve the ocular penetration of cyclosporine^1-3

Explore the technology behind CEQUA ▸

Clinical trial data

See how CEQUA performed
in clinical studies.

View data ▸

Patient savings on CEQUA

Learn about CEQUA Support^™ Specialty Pharmacy for your commercially insured patients.

Learn more ▸

Indications and Usage

CEQUA^™ (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Important Safety Information

Warnings and Precautions

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.

Adverse Reactions

The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.

Please see the Full Prescribing Information.

References: 1. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2018. 2. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. 3. US Patent 9,937,225 B2.